Find a Clinical Trial

Showing 171 - 175 of 175 Trials

Pilot Study to Assess Feasibility, Acceptability, and Efficacy of a Food Navigation and Food DeliveryIntervention to Reduce Food Insecurity Among Patients with Metastatic Breast Cancer

Principal Investigator:

Claire Sathe, MD

Contact Number:

212-342-5162

Population:

Adult

Phase:

NA

The purpose of this research study to find out how we can best help patients with metastatic (advanced) breast cancer who sometimes worry not having enough food and provide resources to access the food that they need. We want to test an intervention by taking surveys to determine how it affects the patients, their food environment, and their mental health. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must have access to smartphone, tablet, or any type of telephone to complete surveys - Must be able to speak English or Spanish
Pilot Randomized Pediatric RISE (Resource Intervention to Support Equity) Feasibility Study

Principal Investigator:

Melissa P. Beauchemin, PhD, MSN, BSN, BA, CPNP-PC, CPON, FAAN

Contact Number:

212-342-5162

NCT Number:

NCT06283251

Population:

Pediatrics

Phase:

NA

The purpose is to determine the feasibility of studying a new guaranteed income intervention called PediRISE among poverty-exposed families with a new diagnosis of childhood cancer at Columbia University. Are you Eligible? (Inclusion Criteria) >Patient must be < 17 years of age >Patient diagnosed with de novo cancer >Patient has established care at a study site and initiated cancer-directed therapy in the prior 2-months >Patient planned to receive at least 4-months of cancer-directed therapy at study site >Parent/guardian screened positive for self-reported low-income (<...
RANDOMIZED NON-INFERIORITY TRIAL COMPARING OVERALL SURVIVAL OF PATIENTS MONITORED WITH SERUM TUMOR MARKER DIRECTED DISEASE MONITORING (STMDDM) VERSUS USUAL CARE IN PATIENTS WITH METASTATIC HORMONE RECEPTOR POSITIVE BREAST CANCER

Principal Investigator:

Melissa Accordino, MD

Contact Number:

212-342-5162

NCT Number:

NCT03723928

Population:

Adult

Phase:

NA

The purpose of this study is to determine if overall survival of patients monitored with serum tumor marker direct disease monitoring (STMDDM) is as good as the overall survival of patients monitored with the usual care. Are you Eligible? (Inclusion Criteria) Do you have hormone positive, HER-2 negative, metastatic breast cancer? Are you 18 years of age or older? Are you willing to be monitored for your disease for the duration of this study?
Repetitive Transcranial Magnetic Stimulation for Enhancing Motor Recovery in Post-Operative Brain Tumor Patients

Principal Investigator:

Brian John Andrew Gill, MD

Contact Number:

212-342-5162

NCT Number:

NCT07530536

Population:

Adult

Phase:

NA

Background: When doctors perform surgery to remove brain tumors, their goal is to take out as much of the tumor as possible while keeping the patient's brain functions intact. However, sometimes patients have trouble with movements like walking or using their hands after surgery. One reason for this is unintentional damage to important areas of the brain during the operation. A technique called Transcranial Magnetic Stimulation (TMS) might help patients recover these lost abilities faster. What We're Doing: We're conducting a study to see if TMS can help patients recover their movement...
Sequencing-guided cHemotherapy Optimization using Real-Time Evaluation in Newly Diagnosed DLBCL with circulating tumor DNA: SHORTEN-ctDNA

Principal Investigator:

Hua-Jay J Cherng, MD

Contact Number:

212-342-5162

NCT Number:

NCT06693830

Population:

Adult

Phase:

NA

This research study is studying the phased variant enrichment and detection sequencing (PhasED-seq) circulating tumor DNA (ctDNA) assay in diffuse large B-cell lymphoma (DLBCL). The PhasED-seq assay is a blood test to measure tiny fragments of material released into the blood by lymphoma called circulating tumor DNA. The purpose of this study is to 1) determine whether it is feasible to measure ctDNA in real-time during standard treatment for newly diagnosed DLBCL, and 2) evaluate the outcomes of participants with undetectable ctDNA in the middle of treatment who receive a shortened course of...

Find a Clinical Trial

Principal Investigator:

Contact Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages